Improving Dosing of Vancomycin in Young Infants With Infections

• Status: Completed
• Trial end date: 2021-01-03
• Target enrollment: 0
• Participant gender: All

Summary

Current dosing regimens for vancomycin result in many young infants not reaching the target level of vancomycin in the blood at steady state (when the blood is in equilibrium at 24-48 hours).The purpose of this study is to assess an improved method of calculating the dose of vancomycin ('model-based dosing') in young infants with infections in order for them to achieve the target vancomycin level at steady state. A dosing calculator (which will be available through a web application) will be used for the dose calculation.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Murdoch Childrens Research Institute
• Collaborators: Monash Health; Royal Children's Hospital; Royal Hospital For Women; Sydney Children's Hospitals Network; University of Otago
• Treatments: Vancomycin

Criteria

Inclusion Criteria:

• Infants aged 0 - 90 days old

• Suspected infection requiring treatment with vancomycin for 48 hours or more (as determined by the clinical team)

• Post-Menstrual age (PMA) matched to PMA-group from retrospective control group

Exclusion Criteria:

• Infants with corrected gestational age of less than 25 weeks

• Infants weighing less than 500g

• Known allergy to any glycopeptide antibiotic

• Vancomycin administered within the previous 72 hours

• Infants receiving any form of extracorporeal life support

• Renal impairment

• Previously enrolled in the study